1 * Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent. ‡ Amgen has an additional three biosimilar programs in development which are undisclosed at this time. **Tradename provisionally approved by the United States Food and Drug Administration, This information reflects public disclosures cu rrent as of April 7, 2017. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most recent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is pro viding this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise. © 201 7 Amgen Inc. All rights reserved. 33 pre clinical and clinical targets with STRONG GENETIC SUPPORT The industry’s largest toolkit with 13 MODALITIES* A mix of INNOVATIVE MOLECULES, NEW INDICATIONS, AND BIO SIMILARS A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success. BIOSIMILARS ‡ ABP 215 (biosimilar bevacizumab) Hematology/ Oncology ABP 494 (biosimilar cetuximab) Hematology/ Oncology ABP 710 (biosimilar infliximab) Inflammation ABP 798 (biosimilar rituximab) Hematology/ Oncology & Inflammation ABP 959 (biosimilar eculizumab) Hematology /Oncology ABP 980 (biosimilar trastuzumab) Hematology/ Oncology PHASE ONE PHASE TWO PHASE THREE AMG 176 Hematology/ Oncology AMG 211 Hematology/ Oncology AMG 224 Hematology/ Oncology AMG 899 Cardiovascular BLINCYTO (blinatumomab) Hematology/ Oncology Erenumab Neuroscience AMG 520 Neuroscience Aranesp (darbepoetin alfa) Hematology/ Oncology BLINCYTO (blinatumomab) Hematology/ Oncology AMG 301 Neuroscience AMG 330 Hematology/ Oncology AMG 420 Hematology/ Oncology Tezepelumab Inflammation Enbrel (etanercept) Inflammation Erenumab Neuroscience **EVENITY TM (romosozumab) Bone Health AMG 557 Inflammation AMG 570 Inflammation AMG 592 Inflammation IMLYGIC (talimogene laherparepvec) Hematology/ Oncology KYPROLIS (carfilzomib) Hematology/ Oncology Omecamtiv mecarbil Cardiovascular AMG 820 Hematology/ Oncology AMG 986 Cardiovascular IMLYGIC (talimogene laherparepvec) Hematology/ Oncology Prolia (denosumab) Bone Health Repatha (evolocumab) Cardiovascular Vectibix (panitumumab) Hematolog y/ Oncology KYPROLIS (carfilzomib) Hematology/ Oncology Oprozomib Hematology/ Oncology XGEVA (denosumab) Hematology/ Oncology 2 * Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent. ‡ Amgen has an additional three biosimilar programs in development which are undisclosed at this time. This information reflects public disclosures current as of April 7, 2017. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most re cent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contai ned in this table as a result of new information, future events or otherwise. © 201 7 Amgen Inc. All rights reserved. PHASE ONE Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects. MOLECULE NAME & PRONUNCIATION MODALITY THERAPEUTIC AREA DESCRIPTION AMG 176 Small Molecule Hematology/ Oncology AMG 176 is a small molecule being investigated as a treatment for multiple myeloma. AMG 211 BiTE A ntibody Hematology/ Oncology AMG 211 is an anti-CEA x anti-CD3 (BiTE ) bispecific antibody construct. It is being investigated as a treatment for various cancer types. AMG 211 is being jointly developed in collaboration with MedImmune. AMG 224 Antibody Drug Conjugate Hematology/ Oncology AMG 224 is an antibody drug conjugate being investigated for the treatment of multiple myeloma. AMG 301 Monoclonal Antibody Neuroscience AMG 301 is a human monoclonal antibody that inhibits the type 1 receptor of the pituitary adenylate cyclase-activating polypeptide (PAC1). It is being investigated for migraine prevention. AMG 301 is being jointly developed in collaboration with Novartis. AMG 330 BiTE Antibody Hematology/ Oncology AMG 330 is an anti-CD33 x anti-CD3 (BiTE ) bispecific antibody construct. It is being investigated as a treatment for acute myeloid leukemia. AMG 420 BiTE Antibody Hematology/ Oncology AMG 420 is an anti-BCMA x anti-CD3 (BiTE ) bispecific antibody construct. It is being investigated as a treatment for multiple myeloma. AMG 557 Monoclonal Antibody Inflammation AMG 557 is a human monoclonal antibody that inhibits the action of B7 related protein (B7RP-1). It is being investigated as a treatment for systemic lupus erythematosus. AMG 557 is being jointly developed in collaboration with AstraZeneca. AMG 570 Bispecific Antibody Inflammation AMG 570 is a bispecific antibody-peptide conjugate that targets BAFF and ICOSL. It is being investigated as a treatment for systemic lupus erythematosus. AMG 570 is being jointly developed in collaboration with AstraZeneca. AMG 592 Fusion Protein Inflammation AMG 592 is an IL-2 mutein Fc fusion protein. It is being investigated as a treatment for inflammatory diseases. AMG 820 Monoclonal Antibody Hematology/ Oncology AMG 820 is a human monoclonal antibody that inhibits c-fms and decreases tumor-associated macrophage (TAM) function. It is being investigated as a treatment for various cancer types. AMG 986 n/a Cardiovascular AMG 986 is being investigated for the treatment of heart failure. IMLYGIC (t alimogene laherparepvec) tal im’ oh jeen la her" pa rep’ vek Oncolytic Immunotherapy Hematology/ Oncology IMLYGIC is an oncolytic immunotherapy derived from HSV-1. It is being investigated as a combination treatment in patients with mid-to late-stage metastatic melanoma (Phase 1b/3) and in other cancer types (Phase 1).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!